Sarepta Therapeutics, Inc. (SRPT)
After hours:
| Previous Close | 133.66 |
| Open | 133.60 |
| Bid | 134.81 x 200 |
| Ask | 135.08 x 200 |
| Day's Range | 132.62 - 135.10 |
| 52 Week Range | 55.25 - 159.89 |
| Volume | |
| Avg. Volume | 872,303 |
| Market Cap | 12.764B |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | 314.05 |
| EPS (TTM) | 0.43 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 166.36 |
Simply Wall St.Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) just released its quarterly report and things are looking bullish. It was a...
Business WireGene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
CAMBRIDGE, Mass., May 03, 2024--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year. Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
